Regeneron Pharmaceuticals, Inc.

Company facts

Industry

Pharmaceutical Preparations

Headquarters

Tarrytown, New York

Most recent report

10-Q, filed Jul 30, 2026

Incorporated

New York

Filings on record

1,000+ filings

On EDGAR

CIK 872589

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 3 of 11 sections worth reading, with 1 positive, 5 notable, and 11 negative flags.

• Financial Statements (Item 1)

  Full financials and extensive litigation notes with material numbers and updates.
  Positive

  • Sanofi development balance fully repaid; no further reduction to collaboration revenue starting Q3 2026.
  Notable

  • Acquired IPR&D expenses jumped to $127M in Q2 2026 from $10M, driven by up-front and opt-in payments.
  • New $3B share repurchase program authorized in April 2026; $2.53B remained as of June 30, 2026.
  Negative

  • Court denied motion to dismiss DOJ's March 2024 civil complaint; five more states intervened in June 2025.

• Management's Discussion (Item 2)

  Detailed financials, pipeline, U.S. gov't deal, capital actions. Company-specific numbers.
  Notable

  • April 2026 U.S. agreements impose Most-Favored-Nation pricing for Medicaid and free Otarmeni in exchange for tariff relief through Jan 2029.
  • Acquired IPR&D expenses jumped to $127.0M in Q2 2026 from $10.0M due to upfront payments for Parabilis and others.
  • Board authorized $3.0B share repurchase in April 2026; $2.534B remained as of June 30, 2026.
  Negative

  • Gross margin on net product sales fell to 78% in Q2 2026 from 83% due to Limerick, Ireland manufacturing disruption.

• Risk Factors (Item 1A)

  Company-specific risks: EYLEA decline, Dupixent shift, FDA CRLs, patent challenge, new lawsuit.
  Negative

  • For H1 2026, EYLEA U.S. net product sales declined 41% vs H1 2025 due to biosimilar competition.
  • For H1 2026, Sanofi collaboration revenue (Dupixent profits) rose to 48% of total revenue from 39% a year earlier.
  • In H1 2026, two distributor customers accounted for 76% of total gross product revenue.
  • In October 2025, FDA issued a CRL for the EYLEA HD pre-filled syringe; no assurance of approval timeline.
  • In July 2025, FDA issued a CRL for odronextamab in relapsed/refractory FL due to third-party manufacturing issues.
  • In May 2026, a Phase 3 trial of fianlimab + Libtayo in first-line melanoma missed its primary endpoint vs pembrolizumab.
  • In March 2026, the USPTO instituted post-grant review of a key EYLEA HD patent (U.S. Patent No. 12,168,036).
  • Bulk manufacturing at Limerick, Ireland was interrupted during Q1 and Q2 2026 due to unanticipated facility repairs.
  • In July 2026, a putative securities class action lawsuit was filed against the Company and certain employees.

What changed: Jun 2026 vs. Mar 2026

About 5% of REGN's Jun 2026 10-Q is new information. 35 paragraphs were added, 180 changed, and 63 removed. Below are the most important lines SECSift identified.

• Item 1A 83
• Item 2 51
• Item 1 36
• Item 5 4
• Item 3 1
• Item 4 1
• Item 6 1